Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Cytologically and/or histologically-documented NSCLC~   1. Stage I (\> 2 cm) to IIIA (for participants with N2 disease, only those with 1 single nodal station ≤ 3 cm are eligible) NSCLC according to the 8th edition of American Joint Committee on Cancer staging classification~  2. Amenable to complete surgical resection~  3. Have not received any other therapy for this condition~2. Predicted forced expiratory volume in one second (FEV1) ≥ 50%~3. Predicted diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50%~4. ECOG 0 or 1~5. Adequate organ function~Exclusion Criteria:~1. Participants with small-cell lung cancer or mixed small-cell lung cancer~2. Participants who require or may require pneumonectomy~3. Prior treatment with programmed cell death ligand-1 (PD-L1), PD-L1, or cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors~4. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug.~5. Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:~   1. Participants with vitiligo or alopecia~  2. Participants with hypothyroidism on hormone replacement~  3. Any chronic skin condition that does not require systemic therapy~  4. Participants without active disease in the last 5 years may be included but only after consultation with the study physician~  5. Participants with celiac disease controlled by diet alone~6. Pregnant or breast-feeding female~7. Major surgical procedure within prior 30 days~8. History of active primary immunodeficiency~9. Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV~10. QTc interval (QTc) ≥ 470 ms~11. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent~12. Receipt of live attenuated vaccination within 30 days prior to study entry~13. History of another primary malignancy except for:~    1. Curative-treated malignancy with no known active disease \> 2 years before enrollment on the study~   2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 102 Years
- Healthy Volunteers: f

Study Arms:
- Durvalumab 1500 mg (Type: EXPERIMENTAL): Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
- Durvalumab 1500 mg + Oleclumab 3000 mg (Type: EXPERIMENTAL): Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
- Durvalumab 1500 mg + Monalizumab 750 mg (Type: EXPERIMENTAL): Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
- Durvalumab 1500 mg + Danvatirsen 200 mg (Type: EXPERIMENTAL): Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).